



Patient Record for CIMZIA In-Office Injection Lyophilized Powder for Reconstitution

TODAY'S DATE: / /

PATIENT INFORMATION

Patient name:

DOB: / /

Referring physician:

Attending physician:

VITALS

Temperature:

BP:

/

Pulse:

Respiratory rate:

List any allergies:

PRE-INJECTION ASSESSMENT

HCPs should consult full Prescribing Information before administering CIMZIA to patient. DO NOT administer CIMZIA to patients with an active infection. Utilize the below pre-injection assessment. If "yes" to any of the below questions, please consult with patient's prescriber prior to injecting CIMZIA.

Any signs/symptoms of infection (see temp above)?

Yes No

Exposure to tuberculosis (TB)?

Yes No

Recent travel to areas where TB or mycoses are endemic?

Yes No

Exposure to invasive fungal infections?

Yes No

Pregnant?

Yes No

Recent surgery since last injection?

Yes No

If yes, what surgery and when:

Any upcoming surgeries?

Yes No

If yes, what surgery and when:

Currently taking other biologic(s)?

Yes No

If yes, which biologic(s):

Any recent vaccinations?

Yes No

If yes, which vaccinations and when:

PATIENT SIGNATURE

Patient Signature:

Date:

Indications

- CIMZIA is indicated for the treatment of adults with moderately to severely active rheumatoid arthritis (RA)
- CIMZIA is indicated for the treatment of adult patients with active psoriatic arthritis (PsA)
- CIMZIA is indicated for the treatment of adult patients with active ankylosing spondylitis (AS)
- CIMZIA is indicated for reducing signs and symptoms of Crohn's disease (CD) and maintaining clinical response in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy
- CIMZIA is indicated for the treatment of adults with moderate-to-severe plaque psoriasis (PSO) who are candidates for systemic therapy or phototherapy
- CIMZIA is indicated for the treatment of adults with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation

Important Safety Information

Serious and sometimes fatal side effects have been reported with CIMZIA, including tuberculosis (TB), bacterial sepsis, invasive fungal infections (such as histoplasmosis), and infections due to other opportunistic pathogens (such as Legionella or Listeria). Patients should be closely monitored for the signs and symptoms of infection during and after treatment with CIMZIA. Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers, of which CIMZIA is a member. CIMZIA is not indicated for use in pediatric patients.

Please refer to the full Prescribing Information provided by the UCB representative, and visit CIMZIAhcp.com.

PATIENT AND VIAL INFORMATION

Reminder: Please review the patient's chart to confirm the following tests have been performed:

TB (PPD) test Yes No

CXR test Yes No

HBV test Yes No

Patient name:

DOB: / /

Date of last administration: / / N/A

Today's Date: / /

Diagnosis Code:

Lot Number:

Expiration Date:

DOSING AND ADMINISTRATION

Dose given today: 400 mg (2 injections of 200 mg)

200 mg (1 injection of 200 mg)

CD:

- Loading: 400 mg at weeks 0, 2, and 4
 Maintenance: 400 mg Q4W

RA, PsA, AS, nr-axSpA:

- Loading: 400 mg at weeks 0, 2, and 4
 Maintenance (select one):
 200 mg Q2W / 400 mg Q4W

PSO (Recommended Dosing):

- 400 mg Q2W


PSO (Alternative Dosing):

(considered for patients with body weight ≤ 90 kg)


- Loading: 400 mg at weeks 0, 2, and 4
 Maintenance: 200 mg Q2W

Dose is administered by subcutaneous injection in the abdomen or thigh. Please mark injection location(s) below:

First Injection of 200 mg



Second Injection of 200 mg



Notes:

FOLLOW-UP REMINDERS

Schedule next injection appointment

Date of next injection: / /

Discuss signs/symptoms and instruct patient to call office if side effects occur

FORM COMPLETED BY

Name:

Title:

Signature:

Date:

Important Safety Information

CIMZIA is contraindicated in patients with a history of hypersensitivity reaction to certolizumab pegol or to any of the excipients. Reactions have included angioedema, anaphylaxis, serum sickness, and urticaria.

Other serious side effects have been reported with CIMZIA, including heart failure, anaphylaxis or serious allergic reactions, hepatitis B reactivation, nervous system disorders, blood problems, and certain immune reactions (including a lupus-like syndrome). It is not recommended to administer CIMZIA with other biologic DMARDs due to an increased risk of infections. In pre-marketing controlled trials of all patient populations combined, the most common adverse reactions ($\geq 8\%$) were upper respiratory infections (18%), rash (9%), and urinary tract infections (8%).

Please refer to the full Prescribing Information provided by the UCB representative, and visit CIMZIAhcp.com.



CIMZIA® is a registered trademark of the UCB Group of Companies.
©2019 UCB, Inc., Smyrna, GA 30080. All rights reserved. US-P-CZ-RA-1900037